Michael Scharfenberger
Good afternoon, and welcome to the Jefferies International Healthcare Convention in New York. My identify is Michael Scharfenberger, with the Jefferies Funding Banking Workforce. It’s my nice pleasure to introduce Alexandria Forbes, CEO of MeiraGTx.
Alexandria Forbes
CEO, President & Director
Thanks very a lot, and thanks for inviting me to speak at your convention. So I am simply going to undergo 2 packages that Meira has in the meanwhile. We’re an organization that was constructed on many alternative applied sciences. The primary one we supposed to do was to regulate any gene with oral small molecules, which we will now do, and it is known as our riboswitch expertise, and we’re taking that into the clinic this yr. And I am going to simply point out that program on the finish, however we’ve got our personal manufacturing, which has helped us have 4 late-stage packages, two of which I am going to discuss to you as we speak about and next-generation optimization, which is without doubt one of the causes our packages have been profitable to this point.
Fairly a deep pipeline, however our 4 lead packages, two of them are awaiting submitting and two of them are ending pivotal or beginning Part III. So radiation-induced xerostomia, wholly owned in-house, and that’s in a pivotal examine knowledge, 12-month knowledge might be this time subsequent yr. And we’ve got breakthrough and RMAT, and we’re hoping to file and get approval on the finish of 2027 with a launch in starting of ’28. X-linked RP. We simply — we partnered this with Johnson & Johnson. They purchased it from us. After which we purchased it again from them only recently. And so it is a program the place we’re meaning to get this accepted in Europe and the
